INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

November 30, 2020

INTERCEPT Blood System for Cryoprecipitation has received FDA approal reports Cerus Corporation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

After thawing, Pathogen Reduced Cryoprecipitated Fibrinogen Complex remains transfusion-ready at room temperature for up to 5 days, continuously available for administration over this extended period. This product has been granted an FDA Breakthrough Device designation based on the potential to improve the treatment of massive hemorrhage, a life-threatening medical condition.

“FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “This is an important win for hospitals, clinicians and patients and also represents a new business model for Cerus. We plan to begin selling Pathogen Reduced Cryoprecipitated Fibrinogen Complex in California, Texas, Louisiana and Wisconsin in 2021, with expansion to national distribution in 2022 following anticipated approval of manufacturing site Biologics License Applications.”

In addition, to use for treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex is also indicated for the control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor are not available, for second-line therapy for von Willebrand disease, and for control of uremic bleeding after other treatment modalities have failed.

“Fibrinogen plays a critical role in controlling bleeding, but it has been difficult to provide quickly to massively bleeding patients. The extended room temperature shelf life, after thawing, of pathogen reduced cryoprecipitated fibrinogen complex allows it to be prepared in advance, which is essential because immediate availability will improve time to reversal of coagulopathy,” said Dr. Philip C. Spinella, Professor of Pediatrics and Director of the Critical Care Blood Research Program at Washington University in St. Louis. “I am optimistic that pathogen reduced cryoprecipitated fibrinogen complex will be a valuable tool to add to the tool box of therapies that are needed to support damage control resuscitation for patients with life threatening bleeding.”

In addition to the approval of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a derivative product from its production, called Pathogen Reduced Plasma, Cryoprecipitate Reduced, has also been approved by the FDA for transfusion or therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

For more information about the INTERCEPT Blood System for Cryoprecipitation, visit product website

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.